ALT vs LLY

Altimmune continues to demonstrate significant 10x growth potential, primarily driven by Pemvidutide, its differentiated dual GLP-1/glucagon agonist. The recent FDA Breakthrough Therapy Designation for MASH is a pivotal, highly positive development, substantially de-risking the program and accelerating its path to market leadership in a multi-billion dollar TAM. A bolstered cash position of $340M ...

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...